IRADIMED CORP — Director's Dealing 2020

Apr 3, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IRADIMED CORP (IRMD)
CIK: 0001325618
Period of Report: 2020-03-31

Reporting Person: JOHNSON BRENT (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-03-31	Common Stock	M	4000	$1.48	Acquired	6940	Direct
2020-03-31	Common Stock	S	4000	$20	Disposed	2940	Direct
2020-04-01	Common Stock	M	4000	$1.48	Acquired	6940	Direct
2020-04-01	Common Stock	S	4000	$20.16	Disposed	2940	Direct
2020-04-02	Common Stock	M	1211	$1.48	Acquired	4151	Direct
2020-04-02	Common Stock	S	1211	$20.17	Disposed	2940	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-03-31	Stock Option (Right to Buy)	$1.48	M	4000	Disposed	2023-12-31	Common Stock (4000)	Direct
2020-04-01	Stock Option (Right to Buy)	$1.48	M	4000	Disposed	2023-12-31	Common Stock (4000)	Direct
2020-04-02	Stock Option (Right to Buy)	$1.48	M	1211	Disposed	2023-12-31	Common Stock (1211)	Direct

Footnotes

F1: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019.

F2: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: This transaction was executed in multiple trades at prices ranging from $20.15 to $20.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.38. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F5: This option, representing a right to purchase a total of 199,759 shares, was granted on December 31, 2013 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date. 49,939 shares from this award were previously exercised in December 2015.